• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Current Evidence Cannot Determine Heart Failure Risk in Transgender People

by
November 12, 2026
in Health
Reading Time: 3 mins read
0
Current Evidence Cannot Determine Heart Failure Risk in Transgender People

Current Evidence Cannot Determine Heart Failure Risk in Transgender People

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Current scientific evidence is insufficient to determine whether transgender status or gender-affirming hormone therapy is associated with the risk of developing heart failure, according to a systematic review published in BMC Medicine. While heart failure represents a major cardiovascular condition with a well-characterised epidemiology in the general population, researchers found that existing studies evaluating transgender populations remain constrained by severe methodological fragmentation and inconsistent study designs.

Cardiovascular risk factors have previously been examined in transgender individuals receiving gender-affirming hormone therapy, yet specific evidence evaluating heart failure outcomes in this group has remained scattered across diverse and heterogeneous epidemiological datasets. To address this knowledge gap, a research team led by Lavinia Rech and Erlon O. de Abreu-Silva set out to synthesise available evidence on heart failure in transgender populations and systematically evaluate the methodological factors influencing risk assessment.

The investigators conducted a systematic review that incorporated both administrative health databases and clinical datasets reporting heart failure outcomes in transgender cohorts. For investigations that provided extractable statistical estimates alongside documented or inferred hormone therapy exposure and an identifiable cisgender comparator group, the authors performed exploratory random-effects quantitative syntheses while assessing transgender identification methods, exposure ascertainment, outcome definitions, comparator selection, and study-level risk of bias.

Across the published medical literature, the research team identified only a limited number of eligible investigations, with just seven full-text studies meeting all inclusion criteria. A critical finding of the review was that transgender identification methods, hormone exposure ascertainment protocols, heart failure definitions, comparator groups, and baseline demographic characteristics varied substantially across the included publications.

When the researchers conducted exploratory quantitative syntheses that incorporated suitable conference abstracts alongside full-text publications, the resulting pooled estimates were statistically non-significant yet demonstrated extreme statistical heterogeneity, both when comparing transgender to cisgender individuals and when contrasting transgender men with cisgender women.

Specifically, the exploratory random-effects analysis comparing transgender individuals to cisgender comparators yielded a pooled odds ratio of 1.10 with a 95% confidence interval ranging from 0.60 to 2.01, accompanied by an I-squared heterogeneity value of 98.9%. Similarly, the quantitative synthesis contrasting transgender men with cisgender women produced an odds ratio of 1.04 with a 95% confidence interval of 0.38 to 2.86, alongside an I-squared heterogeneity measurement of 99.5%.

A notable clinical gap highlighted by the systematic review is that none of the evaluated studies systematically distinguished between distinct heart failure phenotypes. This absence of phenotype classification, combined with variable population identification techniques and exposure assessment strategies, represents a major structural barrier that directly prevents researchers from drawing definitive conclusions regarding cardiovascular risk.

The authors conclude that these structural limitations constrain heart failure risk evaluation in transgender populations.

Because the exploratory quantitative syntheses revealed pronounced statistical variation, with heterogeneity exceeding 98 percent across the pooled analyses, the authors emphasized that resolving these clinical uncertainties requires systemic improvements in epidemiological data infrastructure.

Subject of Research: Heart failure risk assessment and methodological limitations in transgender health research

Article Title: Heart failure in transgender people: evidence synthesis and methodological limitations

Article References: Rech, L., Siqueira, A., Siqueira, S., Siepmann, T., & de Abreu-Silva, E. O. (2026). Heart failure in transgender people: evidence synthesis and methodological limitations. BMC Medicine. https://doi.org/10.1186/s12916-026-05399-2

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05399-2

Keywords: heart failure, transgender health, gender-affirming hormone therapy, systematic review, cardiovascular risk, epidemiology, methodological limitations, clinical datasets, administrative datasets, heart failure phenotypes, cisgender comparator, transgender men, cisgender women, heterogeneity, cardiovascular registries, odds ratio

News Source: Ophelia Keating. (November 12, 2026). Current Evidence Cannot Determine Heart Failure Risk in Transgender People. Scienmag.

Tags: administrative datasetscardiovascular registriescardiovascular riskcisgender comparatorcisgender womenclinical datasetsEpidemiologygender-affirming hormone therapyheart failureheart failure phenotypesheterogeneitymethodological limitationsodds ratiosystematic reviewtransgender healthtransgender men
Share12Tweet7Share2ShareShareShare1

Related Posts

Review Details How Age-Associated B Cells Drive Chronic Autoimmune Diseases

Review Details How Age-Associated B Cells Drive Chronic Autoimmune Diseases

November 20, 2026
Preoperative Scopolamine Lowers Postoperative Anxiety and Depression in Gynecological Surgery Patients

Preoperative Scopolamine Lowers Postoperative Anxiety and Depression in Gynecological Surgery Patients

November 20, 2026

Essential Oil and Nisin Combinations Inactivate Food Pathogens in Model Cheese

November 20, 2026

Purpose-Led Framework Distinguishes Smart Health Homes From General Automation Systems

November 20, 2026

POPULAR NEWS

  • Biased Bubble Chain Navigation Helps Indoor Mobile Robots Accommodate Approaching Pedestrians

    Biased Bubble Chain Navigation Helps Indoor Mobile Robots Accommodate Approaching Pedestrians

    29 shares
    Share 12 Tweet 7
  • Thermophilic Fungus Engineered for High-Yield Bacterial Dipeptidyl Peptidase 4 Secretion

    29 shares
    Share 12 Tweet 7
  • Anterior Talar Osteotomy Corrects Equinus Deformity While Preserving Joint Congruence

    29 shares
    Share 12 Tweet 7
  • Biosensor Mouse Shows Mammary Defects Reversed by Estrogen and Genetic Crossing

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Chinese Herbal Decoction Slows Triple-Negative Breast Cancer Growth in Lab Models

Review Details How Age-Associated B Cells Drive Chronic Autoimmune Diseases

Preoperative Scopolamine Lowers Postoperative Anxiety and Depression in Gynecological Surgery Patients

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.